Dravet Syndrome Treatment Market Exhibits Higher Growth Prospects during 2019-2027

Dravet Syndrome Treatment

Dravet syndrome (DS), also known as polymorphic epilepsy and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic brain dysfunction (epileptic encephalopathy). It usually starts in the first year of life and lasts the rest of one's life. Children with Dravet Syndrome Treatment Market experience a variety of seizures, including myoclonic seizures, tonic-clonic seizures, absence seizures, atypical absence seizures, atonic seizures, focal aware or impaired awareness seizures (previously known as partial seizures), and status epilepticus.

Increasing R&D activities for the development of novel drugs for Dravet syndrome, and subsequent approval in key regions such as North America and Europe, are expected to drive growth in the Global Dravet Syndrome Treatment Market in the near future. Epygenix Therapeutics, Inc., a biopharmaceutical company, received orphan drug designation from the US Food and Drug Administration (FDA) in 2017 for its EPX-300, which is indicated for the treatment of Dravet syndrome. The U.S.

Food and Drug Administration granted orphan drug designation to Ovid Therapeutics, a biopharmaceutical company based in the United States, for TAK-935/OV935 in 2017. (FDA). In February 2018, Zogenix Inc. announced that the FDA had granted ZX-008, its Phase III drug for seizures associated with Dravet Syndrome, breakthrough therapy designation.

Regional Analysis of the Dravet Syndrome Treatment Market

Because of increased initiatives and funding by various organizations to support the development of new Dravet syndrome treatments, North America is expected to hold a dominant position in the global Dravet Syndrome Treatment Market. For example, in 2017, The Dravet Syndrome Foundation—a non-profit organization based in the United States dedicated to funding high-quality Dravet syndrome research—invested a total of US$ 3,600,000 in the development of novel Dravet syndrome treatment methods. In 2011, the Dravet Syndrome Foundation awarded an undisclosed sum to OPKO Health, Inc. in the United States to support the company's efforts to develop potential therapeutic agents for the treatment of Dravet syndrome.